.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Cantor Fitzgerald
Julphar
Mallinckrodt
Farmers Insurance
Daiichi Sankyo
Chinese Patent Office
Moodys
Baxter
Boehringer Ingelheim

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,920,383

« Back to Dashboard

Which drugs does patent 8,920,383 protect, and when does it expire?


Patent 8,920,383 protects NORDITROPIN FLEXPRO, LEVEMIR FLEXTOUCH, NOVOLOG FLEXTOUCH, FIASP FLEXTOUCH, RYZODEG 70/30, SAXENDA, TRESIBA, and XULTOPHY 100/3.6, and is included in eight NDAs.

This patent has eight patent family members in nine countries.

Summary for Patent: 8,920,383

Title:Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left
Abstract: A mechanism for preventing setting of a dose, which exceeds the amount of a medicament in a reservoir in an injection device. The device comprises a threaded piston rod, a limiter and a driver. The three elements are arranged such that during dose setting, the limiter is moved towards an end-of-contend position, wherein dose setting is limited. The invention comprises an accumulative and a non-accumulative embodiment. The invention further relates to a mechanism for prevention ejection of a dose exceeding the set dose.
Inventor(s): Enggaard; Christian Peter (Hillerod, DK), Moller; Claus Schmidt (Fredensborg, DK), Markussen; Tom Hede (Bagsvaerd, DK)
Assignee: Novo Nordisk A/S (Bagsvaerd, DK)
Application Number:11/996,409
Patent Claim Types:
see list of patent claims
Use; Device;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-008Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-009Mar 1, 2010BXRXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-010Mar 1, 2010RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNORDITROPIN FLEXPROsomatropin recombinantINJECTABLE;INJECTION021148-011Jan 23, 2015RXNoNo► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncLEVEMIR FLEXTOUCHinsulin detemir recombinantINJECTABLE;SUBCUTANEOUS021536-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncNOVOLOG FLEXTOUCHinsulin aspart recombinantINJECTABLE;SUBCUTANEOUS020986-005Oct 31, 2013RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncFIASP FLEXTOUCHinsulin aspart recombinantSOLUTION;SUBCUTANEOUS208751-002Sep 29, 2017RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncRYZODEG 70/30insulin aspart; insulin degludecSOLUTION;SUBCUTANEOUS203313-001Sep 25, 2015RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncSAXENDAliraglutide recombinantSOLUTION;SUBCUTANEOUS206321-001Dec 23, 2014RXYesYes► Subscribe► SubscribeY► Subscribe
Novo Nordisk IncTRESIBAinsulin degludecSOLUTION;SUBCUTANEOUS203314-001Sep 25, 2015RXYesNo► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 8,920,383

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
05016291Jul 27, 2005
PCT Information
PCT FiledJuly 17, 2006PCT Application Number:PCT/EP2006/007004
PCT Publication Date:February 15, 2007PCT Publication Number: WO2007/017052

Non-Orange Book Patents for Patent: 8,920,383

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,775,953Dose mechanism for an injection device for limiting a dose setting corresponding to the amount of medicament left► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,920,383

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Japan4827922► Subscribe
Japan2009502273► Subscribe
Spain2361563► Subscribe
European Patent Office1909870► Subscribe
Denmark1909870► Subscribe
Germany602006020453► Subscribe
China101227943► Subscribe
Austria499962► Subscribe
Poland1909870► Subscribe
World Intellectual Property Organization (WIPO)2007017052► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cipla
Argus Health
Covington
Federal Trade Commission
McKesson
Citi
Moodys
Dow
Teva
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot